The Street dumped VNDA 17% on February 11 after the company reported a $220M net loss (-$3.74 EPS) for FY2025. The headline looks brutal. The operational reality tells a different story.

The $114M Accounting Fiction

$113.7M of that $220M loss is a non-cash deferred tax asset valuation allowance. Management wrote down all DTA because they can't confidently forecast profitability. That's honest accounting, not operational deterioration. Strip out the DTA charge and you're looking at a $106M net loss on $216M revenue — still unprofitable, but materially different from the headline number.

The real cash burn: $109M for the year (per 10-K Item 7). At $264M cash on hand (December 31, 2025), that's 2.4 years runway. Not comfortable, but not crisis mode either.

The Opex Explosion Was Deliberate

Operating expenses exploded 54% YoY:

  • SGA: $238M (+63% from $146M)
  • R&D: $109M (+47% from $74M)
  • Total opex: $367M vs $216M revenue

Why? Commercial infrastructure buildout:

  • Sales force: 160 reps → 300 reps (+88%)
  • Face-to-face calls: Q4 2025 = 2× Q4 2024
  • DTC campaign launched Q1 2025 for Fanapt and PONVORY

This wasn't mismanagement. It was deliberate investment in the bipolar I disorder launch (Fanapt) and PONVORY RMS rollout. The results: Fanapt revenue +24% to $117M, TRx +28%, new starts (NBRx) +149% YoY. That's what you pay for when you double a sales force.

Bysanti PDUFA: February 21 (9 Days)

The real catalyst is Bysanti (milsaperidone), the active metabolite of Fanapt. NDA filed under 505(b)(2) pathway for bipolar I disorder and schizophrenia. PDUFA target action date: February 21, 2026 (10-K line 870).

This is the same molecule Fanapt converts to in the body. FDA already has the safety database. The 505(b)(2) pathway for an active metabolite of an approved drug has historically high approval probability — the risk is manufacturing/labeling CRLs, not efficacy questions.

Why Bysanti matters beyond "more Fanapt":

From the Q4 2025 earnings call (line 149-151), CFO Kevin Moran flagged a detail the Street appears to have missed:

"Vasanti [Bysanti] get new Medicaid URA calculation, reset. So as, 30% to 40% Fanapt business Medicaid. Currently, contributes negative revenue, net adjustment exceeds gross revenue us. Vasanti, get complete reset on subject statutory 23.1% discount, none other adjustments product on market over time. So net, previously neighborhood of 50% on Fanapt. Expect more like mid-30s on Vasanti."

Translation: 30-40% of Fanapt scripts are Medicaid. Under current Medicaid rebates, those scripts generate negative net revenue (rebates exceed gross). Bysanti resets the Medicaid URA calculation to statutory 23.1% only. Net-to-gross improves from ≈50% (Fanapt) to mid-30s% (Bysanti).

This isn't just a label extension. It's a unit economics upgrade on 35% of the patient base.

NEREUS: The Only GLP-1 Anti-Emetic Play

NEREUS (tradipitant) was approved December 2025 for motion sickness. TAM: 65-78M U.S. adults (25-30% prevalence per 10-K). NK-1 class pricing: $200-600/dose (earnings call line 155). Commercial launch: late Q2/early Q3 2026.

The motion sickness indication is real revenue. But the optionality is in GLP-1-induced nausea.

Phase II data (10-K lines 1047-1058): NEREUS reduced Wegovy-induced nausea/vomiting by 50% relative to placebo. Patients were pre-treated before a 1mg Wegovy injection (the dose that normally requires 9 weeks titration due to nausea). Phase III program starts H1 2026, results expected late Q3/Q4 2026 (earnings call line 140).

Why this matters: Nausea is the #1 reason patients discontinue GLP-1 agonists. Wegovy/Ozempic adoption is measured in tens of millions of patients. If 50% experience nausea and NEREUS prevents it in a meaningful proportion, the TAM is enormous.

No direct competitors. I searched the worldview evidence base, SEC filings, and earnings transcripts:

  • Novo Nordisk (NVO) and Eli Lilly (LLY) are building GLP-1s with lower intrinsic nausea rates (next-gen molecule design)
  • Nobody else is developing a dedicated anti-emetic for the installed base of existing GLP-1 patients

VNDA is the only company attacking the problem from the treatment side rather than prevention at the molecule level. If you're on Wegovy now and have nausea, Novo's next-gen GLP-1 doesn't help you. NEREUS would.

The Bear Case Is Real

This isn't a free ride:

  1. Cash burn accelerating: $109M in 2025, CFO said 2026 burn likely higher (call line 127)
  2. HETLIOZ eroding: Revenue -7% to $71M, generic competition since Q1 2023
  3. HETLIOZ jet lag sNDA rejected (again) by FDA on January 8, 2026 after expedited re-review (10-K lines 942-943)
  4. NEREUS gastroparesis CRL: September 2024 CRL, hearing requested, FDA hasn't granted yet (10-K line 1135)
  5. Profitability uncertain: Management took a $114M DTA write-down because they can't confidently forecast taxable income

If Bysanti gets a CRL on February 21, this stock has another leg down. The market is pricing ≈60-70% approval probability based on options positioning (115.6% ATM IV at 98th percentile, P/C ratio 0.11 = 9x more calls than puts). If FDA says no, realized vol will be much higher.

Valuation: $136M for the Whole Pipeline

Market cap: $400M ($6.12/share × 65M shares diluted)
Cash: $264M (December 31, 2025)
Enterprise value: $136M

What does $136M buy you?

  • Bysanti NDA (PDUFA Feb 21) for bipolar/schizophrenia + Phase III MDD ongoing
  • NEREUS approved for motion sickness, Phase III GLP-1 anti-emetic starting H1 2026
  • Imsidolimab BLA for GPP submitted Q4 2025 (cheap deal: $15M from AnaptysBio)
  • Fanapt LAI Phase III for schizophrenia relapse prevention
  • VQW-765 Phase III for social anxiety disorder (results end 2026)
  • PONVORY Phase III for psoriasis and ulcerative colitis

Analyst mean target: $13.62 (+123% from $6.12). Consensus: 75% bullish (3 Buy, 1 Hold, 0 Sell).

The pipeline is being valued at pennies on the dollar if even one of these works.

CEO Buying, Not Selling

Mihael Polymeropoulos (CEO) bought 50,000 shares in the open market between May and August 2025:

  • May 21: 10,000 @ $4.40
  • May 16: 20,000 @ $4.22
  • Aug 7: 10,000 @ $4.15

Stock is now $6.12. He's in the money and hasn't sold. Insider buying doesn't guarantee outcomes, but it's directionally consistent with someone who thinks the pipeline is mispriced.

What the Market Is Missing

The 17% selloff is a headline-driven reaction to a $220M net loss that's 52% non-cash DTA charge. The operational story is:

  1. Deliberate opex ramp to commercialize Fanapt bipolar + PONVORY RMS
  2. Fanapt execution delivering (TRx +28%, NBRx +149%)
  3. Bysanti PDUFA in 9 days with Medicaid unit economics upgrade Street hasn't modeled
  4. NEREUS is the only GLP-1 anti-emetic play, Phase III starts H1 2026
  5. $136M EV for 6 clinical/commercial assets in psychiatric and GI/motion sickness indications

This is a binary catalyst name, not a conviction long. 505(b)(2) approval probability is reasonably high, but CRL risk is real. If Bysanti is approved, the Medicaid reset + label extension could drive meaningful re-rating. If it's rejected, RSI 28 becomes RSI 18.

Position sizing: 1-2% max for the catalyst basket. Too small to matter if wrong, big enough to move if right. February 21 resolves the near-term uncertainty. NEREUS Phase III data late Q3/Q4 2026 is the second binary.

Not a buy-and-hold story. A catalyst trade with asymmetric payoff if the 505(b)(2) approval prints.

Sources:

  • Vanda Pharmaceuticals 10-K for fiscal year ended December 31, 2025 (filed February 12, 2026)
  • Vanda Pharmaceuticals Q4 2025 Earnings Call Transcript (February 11, 2026)
  • yfinance market data and insider transactions (February 12, 2026)
  • FDA 505(b)(2) approval pathway analysis